NCT06161116 is a Phase 2 clinical trial of MK-6194 in Systemic Lupus Erythematosus, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT06161116?

NCT06161116 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT06161116?

Interventions in NCT06161116: MK-6194, Placebo.

What condition does NCT06161116 study?

NCT06161116 studies Systemic Lupus Erythematosus.

Is NCT06161116 still recruiting?

NCT06161116 is currently terminated. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT06161116

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Terminated Phase 2 Last updated 6 August 2025

What this trial tests

Phase 2 trial testing MK-6194 in Systemic Lupus Erythematosus in 149 participants. Terminated before completion.

Timeline

27 December 2023

Primary endpoint
30 July 2025

30 July 2025

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	149
Start date	27 December 2023
Primary completion	30 July 2025
Estimated completion	30 July 2025
Sites	127 locations across France, Colombia, Italy, Japan, Malaysia, Chile, Poland, Mexico

Drugs / interventions tested

MK-6194 — full drug profile →
Placebo

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

Adults 18 to 75, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MK-6194

Trials testing the same drug.

NCT06821334 — A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) · Phase 1 · completed
NCT06113328 — A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) · Phase 2 · terminated
NCT06649877 — MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013) · Phase 1 · completed
NCT05450198 — Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) · Phase 1 · completed
NCT04924114 — A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) · Phase 1 · completed

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06161116 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing